Company
MMvention Therapeutix, Inc.
First-in-class BACH1 inhibitors with transformative potential as oral therapy for patients with sickle cell disease (SCD) and beyond in collaboration with Novo Nordisk
Also known as IMMvention Therapeutix, Inc, MMvention Therapeutix
- Business model
- B2B
- Legal name
- IMMvention Therapeutix, Inc
Claim, correct or request removal
Record updated 29 September 2026
About
MMvention Therapeutix, Inc. is an early-stage biotechnology company focused on discovering and developing novel oral small-molecule therapeutics
Funding snapshot
- Total raised
- $8.9MSEC form D sum, as of 2026-09-29Source (opens in a new tab)
- Latest round
- Round, $2M2022-12-23
Funding rounds
- Round, 2022
- $2M2022-12-23, SEC form D sold, 4 investors
- Round, 2020
- $6.9M2020-12-07, SEC form D sold, 5 investors
Products
- Web
- BACH1 inhibitors
Loading relationship preview